除尿糖排泄外的心血管益处：基于两项荟萃分析得出的假设。 - Suppr

Suppr

超能文献

Cardiovascular benefits beyond urinary glucose excretion: A hypothesis generated from two meta-analyses.

作者信息

Lin Chu, Cai Xiaoling, Ji Linong

机构信息

Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.

出版信息

Diabetes Obes Metab. 2022 Mar;24(3):550-554. doi: 10.1111/dom.14596. Epub 2021 Nov 24.

DOI:10.1111/dom.14596

PMID:34726334

Abstract

摘要

相似文献

Cardiovascular benefits beyond urinary glucose excretion: A hypothesis generated from two meta-analyses.

Diabetes Obes Metab. 2022 Mar;24(3):550-554. doi: 10.1111/dom.14596. Epub 2021 Nov 24.

Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.

Diabetes Obes Metab. 2022 Mar;24(3):575-577. doi: 10.1111/dom.14588. Epub 2021 Nov 15.

Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials.

Diabetes Obes Metab. 2021 Apr;23(4):1063-1065. doi: 10.1111/dom.14297. Epub 2020 Dec 29.

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3.

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.

Cardiovasc Diabetol. 2014 Oct 26;13:148. doi: 10.1186/s12933-014-0148-1.

SGLT2 inhibitors for primary prevention of cardiovascular events.

J Diabetes. 2020 Jan;12(1):5-7. doi: 10.1111/1753-0407.13004. Epub 2019 Nov 21.

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.

Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265-014-0337-y.

Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease.

Am J Cardiol. 2022 Jul 1;174:188-189. doi: 10.1016/j.amjcard.2022.04.003. Epub 2022 May 9.

Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.

Diabetes Obes Metab. 2021 Jul;23(7):1696-1700. doi: 10.1111/dom.14359. Epub 2021 Mar 12.

The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.

Curr Med Res Opin. 2019 Jul;35(7):1283-1295. doi: 10.1080/03007995.2019.1576479. Epub 2019 Feb 15.

引用本文的文献

Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.

Cardiovasc Diabetol. 2024 Jun 28;23(1):223. doi: 10.1186/s12933-024-02298-9.

Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis.

Acta Diabetol. 2023 Mar;60(3):435-445. doi: 10.1007/s00592-022-02022-7. Epub 2023 Jan 7.

The Urinary Glucose Excretion by Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis.

Front Endocrinol (Lausanne). 2022 Jan 27;12:814074. doi: 10.3389/fendo.2021.814074. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验